pp 1

PP1 (AGL 1872), a specific and effective Src inhibitor, is with IC50 for Lck/Fyn is 5 nM/ 6 nM, respectively.

3MB-PP1 is a bulky purine analog and a Polo-like kinase 1 (Plk1) inhibitor. In cells expressing analog-sensitive Plk1 alleles, 3MB-PP1 blocks mitotic progression and cell division arise by targeting Plk1. 3MB-PP1 specifically inhibits analog-sensitive Ssn3 (Cdk8). 3MB-PP1 inhibits Leu93 Mutant Zipper-interacting protein kinase with IC50 of 2 μM. 3MB-PP1 can be used for the research of cell division and hypha formation of Candida albicans.

1-NM-PP1 (PP1 Analog II) is a cell-permeable PP1 analog that acts as a potent and selective inhibitor of mutant kinases over their wild-type progenitors.

1-Naphthyl PP1 (1-NA-PP 1) is a selective Src inhibitor, targeting v-Src and c-Fyn, c-Abl, CDK2, and CAMK II with IC50 values of 1.0, 0.6, 0.6, 18, and 22 μM, respectively.

3BrB-PP1 is an ATP-competitive analog that exhibits specific inhibitory activity towards protein kinase, particularly effective against protein kinases with mutations in the ATP-binding pocket, such as the Thr97 mutation within Sty1's ATP-binding pocket.

1-Naphthyl PP1 hydrochloride (1-NA-PP 1 hydrochloride) is a selective inhibitor of Src family kinases v-Src.

3-IN-PP1, a potent protein kinase D (PKD) inhibitor, exhibits pan-PKD inhibitory activity with IC50 values of 108 nM for PKD1, 94 nM for PKD2, and 108 nM for PKD3. Additionally, it serves as a broad-spectrum anticancer agent by inhibiting the growth of various tumor cells. 3-IN-PP1 is utilized in cancer research [1].

DSPE-PEG1000-PP1 is a PEG compound composed of DSPE and the PP1 peptide. The PP1 peptide targets inflammatory atherosclerotic plaques. DSPE-PEG1000-PP1 is suitable for drug delivery applications.

DSPE-PEG5000-PP1 is a PEG compound composed of DSPE and the PP1 peptide, which targets inflammatory atherosclerotic plaques. It can be used for drug delivery.

DSPE-PEG2000-PP1 is a PEG compound composed of DSPE and the PP1 peptide. The PP1 peptide specifically targets inflammatory atherosclerotic plaques. DSPE-PEG2000-PP1 is utilized in drug delivery applications.

DSPE-PEG3400-PP1 is a PEG compound composed of DSPE and PP1 peptide. The PP1 peptide targets inflammatory atherosclerotic plaques. DSPE-PEG3400-PP1 can be utilized for drug delivery.

Calyculin A ((-)-Calyculin A), a toxicant in the Japanese marine sponge CDiscodermia calyxC, is a selective and potent inhibitor of protein phosphatase 1 (PP1) and protein phosphatase 2A (PP2A), inducing hyperactivation of cryopreserved bovine spermatozoa and inhibiting radiation-induced gammaH2AX DNA repair disease in human lymphocytes. gammaH2AX DNA repair foci in human lymphocytes.

Okadaic acid is a potent polyether marine toxin that primarily accumulates in the digestive glands of marine mollusks. It is a highly effective and selective inhibitor of protein phosphatases (PPs). By inhibiting these phosphatases, okadaic acid increases the phosphorylation levels of various proteins, acts as a tumor promoter, and induces tau protein phosphorylation. It can be used to establish models of Alzheimer’s disease and skin cancer.

1-PP-myo-InsP5 is a type of inositol pyrophosphate. In mammals, it functions as a signaling molecule by interacting with specific receptors or through non-enzymatic phosphate transfer. Additionally, 1-PP-myo-InsP5 is involved in various biological processes, such as insulin signaling and the regulation of telomere length.

PP2A Cancerous-IN-1 is a potent inhibitor of CIP2A (Cancerous inhibitor of PP2A) and p-Akt, demonstrating significant anti-proliferative effects.

PP5-IN-1 is a potent and competitive serine/threonine protein phosphatase-5 (PP5) inhibitor with potential anticancer activity that induces apoptosis in cancer cells.

1,5-(PP)2-myo-InsP4 is an inositol pyrophosphate that functions as a signaling molecule by binding to specific receptors or facilitating the non-enzymatic transfer of the β-phosphate to phosphorylated serine residues in proteins.

Enpp-1-IN-16 is an inhibitor targeting ENPP1 with potential anti-cancer activity.Enpp-1-IN-16 can be used to study insulin resistance in relation to type II diabetes mellitus and various ENPP1-mediated diseases in the chondrocalcinosis and osteoarthritis classes.

Aliskiren hemifumarate (CGP60536B) is an orally active nonpeptide renin inhibitor with antihypertensive activity.

Enpp/Carbonic anhydrase-IN-1 (compound 1e) is a potent inhibitor of Enpp and carbonic anhydrase, exhibiting IC50s of 1.36, 1.35, 3.00, 0.88, and 1.02 µM for NPP1, NPP2, NPP3, CA-II, and CA-IX respectively. Enpp/Carbonic anhydrase-IN-1 also demonstrates selective antiproliferative activity for cancer cells.

Enpp/Carbonic anhydrase-IN-2 is a potent dual inhibitor of Enpp and carbonic anhydrase, inhibiting NPP1, NPP2, NPP3, CA-IX, CA-XII, with IC50 values of 1.13, 1.07, 0.74, 0.33, 0.68, respectively.Enpp/Carbonic anhydrase-IN-2 induced apoptosis.Enpp/Carbonic anhydrase-IN-2 has antiproliferative activity against cancer cells and low cytotoxicity against normal cells.

Aliskiren (CGP 60536) D6 Hydrochloride is a deuterium-labeled Aliskiren. Aliskiren hemifumarate is a direct and orally active renin inhibitor (IC50: 1.5 nM).

IFB-088 acetate, a benzyl guanidine derivative, is used to treat diseases and cancers associated with the PPP1R15A pathway and associated with protein misfolding stress, Examples include tau disease, synaptic riboprotein disease, polyglutamine and polyalanine diseases, leukodystrophy, cystic fibrosis, multiple sclerosis, lysosome storage disorders, amyloidosis diseases, inflammation, metabolic disorders, cardiovascular diseases, osteoporosis, neurological trauma, and more.

2OH-BNPP1 is a BUB1 kinase, a Ser/Thr kinase inhibitor, it used for the treatment of cancer.